Literature DB >> 16079899

Phosphodiesterase 11 (PDE11): is it a player in human testicular function?

S H Francis1.   

Abstract

PDE11, the newest member of the PDE family of phosphodiesterases, has become the center of controversy. Four splice variants were recently identified, PDE11A1-4. Historical data have suggested that PDE11A3 is found in the testis while PDE11A4 is found in the prostate. The controversial issue is the inhibition of PDE11 by tadalafil. In the light of tadalafil's commercial success, its inhibition of PDE11A has been the subject of heated debate. A variety of published reports addressed this issue, suggesting that the target organ of tadalafil's inhibition, the testis, is not adversely affected. Daily tadalafil given to healthy volunteers did not alter semen analysis parameters or blood hormonal parameters, seemingly mitigating the clinical effect of the PDE11 inhibition. However, two recent papers published in this journal have added fuel to this proverbial fire. In this perspective, Sharron Francis, a noted PDE expert, and a co-author of one of the recent papers mentioned above, sheds further light on this contested topic.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16079899     DOI: 10.1038/sj.ijir.3901377

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  7 in total

Review 1.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Authors:  Isaac Levy; Anelia Horvath; Monalisa Azevedo; Rodrigo Bertollo de Alexandre; Constantine A Stratakis
Journal:  Curr Opin Pharmacol       Date:  2011-10-31       Impact factor: 5.547

Review 2.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 3.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

Review 4.  Tadalafil: in pulmonary arterial hypertension.

Authors:  Jamie D Croxtall; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2010-03-05       Impact factor: 9.546

Review 5.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

6.  Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors.

Authors:  Nermin S Ahmed; Bernard D Gary; Hethar N Tinsley; Gary A Piazza; Stefan Laufer; Ashraf H Abadi
Journal:  Arch Pharm (Weinheim)       Date:  2010-12-22       Impact factor: 3.751

Review 7.  Phosphodiesterase type 5 and cancers: progress and challenges.

Authors:  Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano
Journal:  Oncotarget       Date:  2017-10-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.